Myotonic dystrophy type 1 in the COVID-19 era.

Ilic-Zivojinovic Jelena Katarina DjurdjevicIvo BozovicGiovanni MeolaMarina PericAna Azanjac ArsicIvana BastaVidosava Rakocevic-StojanovicStojan Z Peric

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

The percentage of DM1 patients who suffered from COVID-19 was like in general population, but with more severe forms in DM1, especially in patients with longer DM1 duration. The study indicated an overall favorable safety profile of COVID-19 vaccines among individuals with DM1 and its ability to protect them from severe COVID-19.

Keyphrases

coronavirus disease
sars cov
early onset
respiratory syndrome coronavirus
type diabetes
glycemic control
metabolic syndrome
drug induced
insulin resistance
duchenne muscular dystrophy